Composite medicine for reducing mastitis and preparation method thereof

By preparing a compound drug containing frog oil, deer antler disc, vitamin C, and maltodextrin, the problem of preserving the active ingredients of frog oil was solved, achieving a significant reduction in mastitis and enhancing the drug's functionality and stability.

CN118903210APending Publication Date: 2024-11-08BAISHAN BAIMUBAI BIOTECHNOLOGY CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410962074.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

Smart Images

  • Figure CN118903210A_ABST
    Figure CN118903210A_ABST
Patent Text Reader

Abstract

The invention discloses a composite medicine for reducing mastitis and a preparation method thereof. The composite medicine comprises the following components in parts by mass: 3-8 parts of rana japonica oil, 5-25 parts of coronet, 5-15 parts of vitamin C and 60-65 parts of maltodextrin. The composite medicine is rich in various nutritional ingredients, and has the functions of resisting oxidation, enhancing skin reparability and activity, activating uterus, relieving fatigue, improving immunity, inhibiting hyperplasia of mammary glands and relieving mastitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of forest frog oil products, and in particular to a composite medicine for reducing mastitis and a preparation method thereof. Background Art

[0002] Rana oil mostly refers to the oviduct of mature female Rana, which contains a large amount of protein, fat, carbohydrates, vitamins and natural sex hormone estradiol. According to the theory of traditional Chinese medicine, Rana oil has the special effects of "tonifying the kidney and essence, moistening the lungs and nourishing yin", and has a certain effect on helping weak body and weak immunity. It is a tonic product with extremely high nutritional value. Rana oil has excellent health care functions, but its functional ingredients are difficult to preserve, and it is easy to lose activity during the processing process. It is inconvenient to eat and not easy to carry and store. In addition, the nutritional effect of Rana oil products in the prior art for reducing mastitis still needs to be improved.

[0003] Therefore, it is necessary to develop a compound drug of Rana sylvatica oil that is rich in multiple nutrients and can ensure that the active ingredients are not easily lost during storage and processing, and can effectively reduce mastitis. Summary of the invention

[0004] In order to solve the above technical problems, the purpose of the present invention is to provide a composite drug for reducing mastitis and a preparation method thereof. The composite drug is rich in various nutrients and has the functions of anti-oxidation, enhancing skin repair and activity, activating the uterus, relieving fatigue, improving immunity, inhibiting breast hyperplasia and relieving mastitis.

[0005] In order to achieve the above technical objectives and the above technical effects, the present invention is implemented through the following technical solutions:

[0006] A composite medicine for reducing mastitis comprises the following components by weight: 3-8 parts of forest frog oil, 5-25 parts of deer antler plates, 5-15 parts of vitamin C and 60-65 parts of maltodextrin.

[0007] Preferably, the composite drug for reducing mastitis comprises the following components in parts by mass: 8 parts of forest frog oil, 25 parts of deer antler plates, 5 parts of vitamin C and 60 parts of maltodextrin.

[0008] The preparation method of the composite medicine for reducing mastitis comprises the following steps:

[0009] (1) foaming the frog oil with a foaming agent to obtain the swollen frog oil;

[0010] (2) The antler disc, vitamin C, maltodextrin and Rana sylvatica oil are mixed, freeze-dried, ultrafinely ground and screened to obtain a composite drug.

[0011] Furthermore, in step (1), the foaming agent includes 0.1-0.2% sodium citrate, 0.6-0.8% NaCl, 0.1-0.2% sodium dihydrogen phosphate, and the balance is water.

[0012] Furthermore, in step (1), during the foaming, low-frequency ultrasonic waves of 0.3 to 0.7 MHz are used for ultrasonic oscillation.

[0013] Furthermore, the volume increase rate of the foamed frog oil is 3200% to 5200%.

[0014] Furthermore, the freeze-drying process of step (2) is carried out using a vacuum freeze dryer; the freeze-drying process is as follows: the condenser temperature of the freeze dryer is lowered to -40°C in advance and maintained for 45 minutes; the vacuum degree of the freeze dryer is adjusted to below 80Pa, the temperature is increased to 5°C within 1 hour, and then the vacuum degree is adjusted to 20Pa, kept warm for 2 hours, and the temperature is increased to 50°C within 1 hour and kept warm for 8 hours.

[0015] The beneficial effects of the present invention are:

[0016] (1) The Rana sylvatica oil in the composite drug of the present invention has the functions of anti-oxidation, improving skin vitality, and repairing skin damage; the antler plate powder has the functions of inhibiting breast hyperplasia and relieving mastitis; and Vc has the functions of anti-oxidation and delaying aging;

[0017] (2) The vitamin C in it can protect the unsaturated fatty acids in the frog oil and reduce the nutritional damage caused by the loss of unsaturated fatty acids;

[0018] (3) The deer antler plate has a significant inhibitory effect on chronic inflammation, and vitamin C can help it exert its anti-inflammatory effect;

[0019] (4) Rana oil has the function of relieving fatigue and improving immunity, which can ensure the mental state during disease treatment and pain.

[0020] (5) Rana oil is mild in nature, while antler disc is warm in nature. Vitamin C can reduce the sexual heat problem caused by taking antler disc;

[0021] (6) The present invention utilizes low-frequency ultrasound of 0.3 to 0.7 MHz to perform ultrasonic oscillation on the foaming process. Low-frequency ultrasound has the characteristics of mechanical vibration and thermal effect. At the same time, the tiny vibration and friction between cells generated by low-frequency ultrasound can increase the permeability of cell membranes, destroy the tight connection of cells, increase the water permeability of cells, reduce the water absorption and expansion of cells, effectively inhibit the expansion rate of forest frog oil during foaming, avoid the problem of expansion and breakage of forest frog oil during foaming, and improve the nutrient absorption efficiency of forest frog oil;

[0022] (7) The composite drug is prepared by vacuum freeze-drying technology, which can improve the dehydration effect while maintaining the efficacy of various components, thereby protecting the drug components and preventing loss. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the test result of total antioxidant capacity of mouse blood;

[0024] Figure 2 These are the results of detecting inflammation levels in mouse breast tissue. DETAILED DESCRIPTION

[0025] The technical solutions in the present invention will be described clearly and completely below in conjunction with specific embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0026] The invention provides a composite medicine for reducing mastitis, which comprises the following components in parts by mass: 3-8 parts of forest frog oil, 5-25 parts of deer antler plates, 5-15 parts of vitamin C and 60-65 parts of maltodextrin.

[0027] Preferably, the composite drug for reducing mastitis comprises the following components in parts by mass: 8 parts of forest frog oil, 25 parts of deer antler plates, 5 parts of vitamin C and 60 parts of maltodextrin.

[0028] The preparation method of the composite medicine for reducing mastitis comprises the following steps:

[0029] (1) foaming the frog oil with a foaming agent to obtain the swollen frog oil;

[0030] In step (1), the foaming agent comprises 0.1-0.2% sodium citrate, 0.6-0.8% NaCl, 0.1-0.2% sodium dihydrogen phosphate, and the balance is water;

[0031] In step (1), during the foaming, ultrasonic oscillation is performed using low-frequency ultrasonic waves of 0.3 to 0.7 MHz;

[0032] The volume increase rate of the Rana sylvatica oil after foaming is 3200% to 5200%;

[0033] (2) mixing the antler plate, vitamin C, maltodextrin and Rana sylvatica oil, freeze-drying, ultrafine grinding and screening to obtain a composite drug;

[0034] The freeze-drying process of step (2) is carried out using a vacuum freeze dryer; the freeze-drying process is as follows: the condenser temperature of the freeze dryer is lowered to -40°C in advance and maintained for 45 minutes; the vacuum degree of the freeze dryer is adjusted to below 80Pa, the temperature is increased to 5°C within 1 hour, and then the vacuum degree is adjusted to 20Pa, kept warm for 2 hours, and the temperature is increased to 50°C within 1 hour and kept warm for 8 hours.

[0035] Example 1

[0036] A composite drug A for reducing mastitis comprises the following components in parts by mass: 3 parts of forest frog oil, 5 parts of deer antler plates, 10 parts of vitamin C and 60 parts of maltodextrin.

[0037] Example 2

[0038] A composite drug B for reducing mastitis comprises the following components in parts by mass: 3 parts of forest frog oil, 15 parts of deer antler plates, 15 parts of vitamin C and 60 parts of maltodextrin.

[0039] Example 3

[0040] A composite drug C for reducing mastitis comprises the following components in parts by mass: 3 parts of forest frog oil, 25 parts of deer antler plates, 5 parts of vitamin C and 60 parts of maltodextrin.

[0041] Example 4

[0042] A composite drug D for reducing mastitis comprises the following components in parts by mass: 5 parts of forest frog oil, 25 parts of deer antler plates, 5 parts of vitamin C and 60 parts of maltodextrin.

[0043] Example 5

[0044] A composite drug E for reducing mastitis comprises the following components in parts by mass: 5 parts of forest frog oil, 5 parts of deer antler plates, 15 parts of vitamin C and 60 parts of maltodextrin.

[0045] Example 6

[0046] A composite drug F for reducing mastitis comprises the following components in parts by mass: 5 parts of forest frog oil, 15 parts of deer antler plates, 10 parts of vitamin C and 60 parts of maltodextrin.

[0047] Example 7

[0048] A composite drug G for reducing mastitis comprises the following components in parts by mass: 8 parts of forest frog oil, 15 parts of deer antler plates, 15 parts of vitamin C and 60 parts of maltodextrin.

[0049] Example 8

[0050] A composite drug H for reducing mastitis comprises the following components in parts by mass: 8 parts of forest frog oil, 25 parts of deer antler plates, 5 parts of vitamin C and 60 parts of maltodextrin.

[0051] Example 9

[0052] A composite medicine I for reducing mastitis comprises the following components in parts by mass: 8 parts of forest frog oil, 5 parts of deer antler plates, 10 parts of vitamin C and 60 parts of maltodextrin.

[0053] The formulations of Examples 1-9 are shown in Table 1.

[0054] Table 1

[0055] Grouping A B C D E F G H I Rana oil 3 servings 3 servings 3 servings 5 servings 5 servings 5 servings 8 servings 8 servings 8 servings Deer antler plate 5 servings 15 servings 25 servings 25 servings 5 servings 15 servings 15 servings 25 servings 5 servings Vitamin C 10 servings 15 servings 5 servings 5 servings 15 servings 10 servings 15 servings 5 servings 10 servings Maltodextrin 60 servings 60 servings 60 servings 60 servings 60 servings 60 servings 60 servings 60 servings 60 servings

[0056] The preparation method of the composite drug for reducing mastitis of Examples 1-9 comprises the following steps:

[0057] (1) foaming the frog oil with a foaming agent to obtain the swollen frog oil;

[0058] The foaming agent in step (1) comprises 0.1% sodium citrate, 0.6% NaCl, 0.1% sodium dihydrogen phosphate, and the balance is water;

[0059] In step (1), during the foaming, ultrasonic oscillation is performed using a low-frequency ultrasonic wave of 0.3 MHz;

[0060] (2) mixing the antler plate, vitamin C, maltodextrin and Rana sylvatica oil, freeze-drying, ultrafine grinding and screening to obtain a composite drug;

[0061] The freeze-drying process of step (2) is carried out using a vacuum freeze dryer; the freeze-drying process is as follows: the condenser temperature of the freeze dryer is lowered to -40°C in advance and maintained for 45 minutes; the vacuum degree of the freeze dryer is adjusted to below 80Pa, the temperature is increased to 5°C within 1 hour, and then the vacuum degree is adjusted to 20Pa, kept warm for 2 hours, and the temperature is increased to 50°C within 1 hour and kept warm for 8 hours.

[0062] The above 9 groups of compound drugs were used to feed the mastitis model mice, and the normal mice were used as the blank group. The total antioxidant capacity of the mouse blood and the level of breast tissue inflammation were measured to test the antioxidant capacity of the mastitis model group and the blank group. Figure 1 and Figure 2 shown.

[0063] Depend on Figure 1 It can be seen that compared with the blank group, the total antioxidant capacity of mice in the mastitis model group was significantly reduced, while after feeding the AI ​​group with the compound drug, the total antioxidant capacity was significantly restored. Among them, the C, E, F, and H groups performed better.

[0064] The level of IF-1β in breast tissue indicates the inflammatory status of the tissue. Figure 2 It can be seen that compared with the blank group, the IF-1β level in the breast tissue of mice in the mastitis model group was significantly increased, and after feeding the compound drug, it was found that there was a relief effect, among which Group H had the best effect.

[0065] Therefore, the components of group H are selected as the best components of the composite medicine of the present invention, that is, the composite medicine for reducing mastitis includes the following components in parts by mass: 8 parts of forest frog oil, 25 parts of antler plate powder, 5 parts of vitamin C, and 60 parts of maltodextrin.

[0066] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.

[0067] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A composite drug for reducing mastitis, characterized in that: The invention comprises the following components in parts by weight: 3-8 parts of forest frog oil, 5-25 parts of deer antler plates, 5-15 parts of vitamin C and 60-65 parts of maltodextrin.

2. A composite drug for reducing mastitis according to claim 1, characterized in that: The invention comprises the following components in parts by mass: 8 parts of forest frog oil, 25 parts of deer antler plates, 5 parts of vitamin C and 60 parts of maltodextrin.

3. A method for preparing the composite drug for reducing mastitis according to claim 1 or 2, characterized in that: The steps include: (1) foaming the frog oil with a foaming agent to obtain the swollen frog oil; (2) The antler disc, vitamin C, maltodextrin and Rana sylvatica oil are mixed, freeze-dried, ultrafinely ground and screened to obtain a composite drug.

4. The method for preparing the composite medicine for reducing mastitis according to claim 3, characterized in that: In step (1), the foaming agent includes 0.1-0.2% sodium citrate, 0.6-0.8% NaCl, 0.1-0.2% sodium dihydrogen phosphate, and the balance is water.

5. The method for preparing the composite medicine for reducing mastitis according to claim 3, characterized in that: In step (1), during the foaming, low-frequency ultrasonic waves of 0.3 to 0.7 MHz are used for ultrasonic oscillation.

6. The method for preparing the composite medicine for reducing mastitis according to claim 3, characterized in that: The volume increase rate of the frog oil after foaming is 3200% to 5200%.

7. The method for preparing the composite medicine for reducing mastitis according to claim 3, characterized in that: The freeze-drying process of step (2) is carried out using a vacuum freeze dryer; the freeze-drying process is as follows: the condenser temperature of the freeze dryer is lowered to -40°C in advance and maintained for 45 minutes; the vacuum degree of the freeze dryer is adjusted to below 80Pa, the temperature is increased to 5°C within 1 hour, and then the vacuum degree is adjusted to 20Pa, kept warm for 2 hours, and the temperature is increased to 50°C within 1 hour and kept warm for 8 hours.

Citation Information

Patent Citations

  • Instant fish maw milk jelly rich in protein and preparation method of instant fish maw milk jelly

    CN115669733A